Preparation of high-quality oxo process alcohols from inconstant raw material sources
US-9914681-B2 · Mar 13, 2018 · US
Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
US11519020B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11519020-B2 |
| Application number | US-201815989371-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 25, 2018 |
| Priority date | May 25, 2018 |
| Publication date | Dec 6, 2022 |
| Grant date | Dec 6, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Disclosed herein are methods and compositions for associating a genetic variant with intraretinal fluid. Also disclosed herein are methods and compositions for associating a genetic variant with visual acuity, anatomic outcomes or treatment frequency.
First claim
Opening claim text (preview).
What is claimed is: 1. A method for treating a macular degeneration patient with a vascular endothelial growth factor (VEGF) inhibitor, comprising the steps of: determining whether the patient has one or more of the genetic variants rs2056688, rs5962084, rs5962087, rs5915722, and rs5962095, by performing or having performed a genotype assay on a DNA sample obtained from the patient; and modifying the dosing frequency after about one year of administering about 2 mg of the VEGF inhibitor to the patient from about every 8 weeks to about every 9 to 12 weeks to a patient having one or more of the genetic variants; or modifying the dosing frequency after about one year of administering about 2 mg of the VEGF inhibitor to the patient from about every 8 weeks to about every 4 to 6 weeks to a patient not having one or more of the genetic variants. 2. The method of claim 1 , wherein the genetic variant is rs5962087. 3. The method of claim 1 , wherein the genetic variant is rs5962084. 4. The method of claim 1 , wherein the genetic variant is rs2056688. 5. The method of claim 1 , wherein the VEGF inhibitor is ranibizumab or aflibercept. 6. The method of claim 1 , wherein the VEGF inhibitor is aflibercept. 7. The method of claim 4 , wherein the VEGF inhibitor is aflibercept. 8. The method of claim 1 , wherein the dosing frequency of administering about 2 mg of the VEGF inhibitor to the patient having one or more of the genetic variants is modified from about every 8 weeks to about every 9 weeks. 9. The method of claim 1 , wherein the dosing frequency of administering about 2 mg of the VEGF inhibitor to the patient having one or more of the genetic variants is modified from about every 8 weeks to about every 10. 10. The method of claim 1 , wherein the dosing frequency of administering about 2 mg of the VEGF inhibitor to the patient having one or more of the genetic variants is modified from about every 8 weeks to about every 11 weeks. 11. The method of claim 1 , wherein the dosing frequency of administering about 2 mg of the VEGF inhibitor to the patient having one or more of the genetic variants is modified from about every 8 weeks to about every 12 weeks. 12. The method of claim 1 , wherein the dosing frequency of administering about 2 mg of the VEGF inhibitor to the patient not having one or more of the genetic variants is modified from about every 8 weeks to about every 4 weeks. 13. The method of claim 1 , wherein the dosing frequency of administering about 2 mg of the VEGF inhibitor to the patient not having one or more of the genetic variants is modified from about every 8 weeks to about every 5 weeks. 14. The method of claim 1 , wherein the dosing frequency of administering about 2 mg of the VEGF inhibitor to the patient not having one or more of the genetic variants is modified from about every 8 weeks to about every 6 weeks. 15. The method of claim 1 , wherein the genetic variant is rs5915722. 16. The method of claim 1 , wherein the genetic variant is rs5962095.
Assignees
Inventors
Classifications
for diseases caused by alterations of genetic material · CPC title
for computer-aided diagnosis, e.g. based on medical expert systems · CPC title
Fab or Fab' · CPC title
Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism · CPC title
- A61P27/00Primary
Drugs for disorders of the senses · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11519020B2 cover?
- Disclosed herein are methods and compositions for associating a genetic variant with intraretinal fluid. Also disclosed herein are methods and compositions for associating a genetic variant with visual acuity, anatomic outcomes or treatment frequency.
- Who is the assignee on this patent?
- Regeneron Pharma
- What technology area does this patent fall under?
- Primary CPC classification A61P27/00. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Dec 06 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).